Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SCN9A | Q15858 | 15/20 | 0.43 |
| ▸ | ADORA2A | P29274 | 3/20 | 0.43 |
| ▸ | ADORA1 | P30542 | 2/20 | 0.43 |
| ▸ | ADORA2B | P29275 | 1/20 | 0.43 |
| ▸ | USP1 | O94782 | 1/20 | 0.43 |
| ▸ | WDR48 | Q8TAF3 | 1/20 | 0.43 |
| ▸ | LRRK2 | Q5S007 | 1/20 | 0.41 |
| ▸ | SCN10A | Q9Y5Y9 | 1/20 | 0.38 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.38 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.38 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4583807 | 0.89 | ADORA2A (0.44) | ADORA2AADORA1LRRK2 | |
| SCHEMBL4585198 | 0.85 | ADORA2A (0.47) | SCN9AADORA2AADORA1ADORA2B | |
| SCHEMBL4585042 | 0.84 | ADORA2A (0.47) | ADORA2AADORA1ADORA2BUSP1WDR48 | |
| SCHEMBL4584974 | 0.84 | IRAK4 (0.44) | SCN9AADORA2AADORA1ADORA2B | |
| SCHEMBL4585798 | 0.83 | ADORA2A (0.43) | ADORA2AADORA1USP1WDR48 | |
| SCHEMBL4585752 | 0.82 | ADORA2A (0.43) | ADORA2AADORA1USP1WDR48LRRK2 | |
| SCHEMBL4584074 | 0.82 | ADORA2A (0.50) | ADORA2AADORA1 | |
| SCHEMBL4584900 | 0.82 | ADORA2A (0.44) | ADORA2AADORA1 | |
| SCHEMBL4584010 | 0.81 | ADORA2A (0.64) | ADORA2AADORA1ADORA2B | |
| SCHEMBL4586478 | 0.81 | ADORA2A (0.46) | ADORA2AADORA1ADORA2B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7407961-B2 | Pyrazine derivatives and pharmaceutical use thereof | ASTELLAS PHARMA INC. (JP) | 2008-08-05 | — | — | US | disclosed |
| CN-1871231-A | Pyrazine derivatives and pharmaceutical use thereof | ASTELLAS PHARMA INC (JP) | 2006-11-29 | — | — | CN | disclosed |
| US-20050113387-A1 | Pyrazine derivatives and pharmaceutical use thereof | FUJISAWA PHARMACEUTICAL CO. LTD. (JP) | 2005-05-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050113387-A1 | Pyrazine derivatives and pharmaceutical use thereof | ADORA2A, P2RX5, ADORA1 | SCN9A 1157/4885ADORA2A 1/4885ADORA1 3/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.